<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77336">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02036645</url>
  </required_header>
  <id_info>
    <org_study_id>D4750C00001</org_study_id>
    <nct_id>NCT02036645</nct_id>
  </id_info>
  <brief_title>SAD/MAD Study to Assess Safety, Tolerability, PK &amp; PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, drug levels and effects on the body of 1
      or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy
      elderly people.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>To Assess Safety &amp; Tolerability of MEDI1814 by a panel of adverse event measures: Physical exam, Vital signs, ECG, clinical laboratory testing, MRI, Columbia Suicide Severity Rating Scale</measure>
    <time_frame>All visits from screening up to 113 days post single dose/169 days post multiple dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Vital signs, ECG, clinical laboratory testing, MRI, Columbia Suicide Severity Rating Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Assess Pharmacokinetics of MEDI1814 in terms of: ﻿Cmax, Cmin, tmax, AUC, t1/2, CL and Vz for SAD and for MAD First dose: Cmax, Cmin, tmax, AUC and Third Dose: Cmax, Cmin, tmax, AUC, t1/2, CL, Vz, Vss and accumulation rations</measure>
    <time_frame>Baseline up to 113 days post single dose/169 days post multiple dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>﻿Blood samples will be taken for assessments. Single Ascending Dose: Cmax, Cmin, tmax, AUC, t1/2, CL and Vz. Mutiple Ascending Dose First dose: Cmax, Cmin, tmax, AUC, and for Third Dose: Cmax, Cmin, tmax, AUC, t1/2, CL, Vz, Vss and accumulation ratios</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess Pharmacodynamics of MEDI1814 in terms of a) blood biomarkers: total amyloid beta 1-42 and b) CSF biomarkers: total and free amyloid beta 1-42 and total amyloid beta 1-40</measure>
    <time_frame>Baseline up to 113 days post single dose/169 days post multiple dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood and CSF samples will be taken for assessment. Blood biomarkers: total amyloid beta 1-42 and CSF biomarkers: total and free amyloid beta 1-42; total amyloid beta 1-40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess Immunogenicity of MED1814 in terms of anti drug antibody detection</measure>
    <time_frame>Baseline up to 113 days post dose for single dose/169 days post multiple dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood samples will be taken for assessment of screening results and anti drug antibody (ADA) titre post dosing</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To Assess Exploratory Measures of ApoE genotype, central and peripheral protein biomarkers and MCI screen</measure>
    <time_frame>Basline up to 113 days post single dose/169 days post mutiple dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Samples will be taken to assess ApoE genotype, central and peripheral protein biomarkers. A novel cognitive assessment scale, the MCI screen, will be assessed for utility in future studies</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Mild-Moderate Alzheimer's Disease</condition>
  <condition>Healthy Elderly</condition>
  <arm_group>
    <arm_group_label>MEDI1814 IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI1814 Sub Cutaneous Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI1814 for IV injection</intervention_name>
    <description>Monoclonal antibody for IV Injection</description>
    <arm_group_label>MEDI1814 IV</arm_group_label>
    <arm_group_label>IV Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI1814 for Subcutaneous Injection</intervention_name>
    <description>Monoclonal antibody for subcutaneous injection</description>
    <arm_group_label>MEDI1814 Sub Cutaneous Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IV Placebo</intervention_name>
    <description>Placebo for IV injection</description>
    <arm_group_label>IV Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for Subcutaneous Injection</intervention_name>
    <description>Subcutaneous Placebo Injection</description>
    <arm_group_label>Subcutaneous Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Male and female (non child bearing potential) subjects Mild-moderate
        Alzheimer's Disease

        Exclusion Criteria History or evidence of significant autoimmune disease Presence of
        psychiatric disorder which would affect completion of the study Current serious or
        unstable clinically important illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C Alexander, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glendale Parexel Early Phase Clinical Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert C Alexander, MD</last_name>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>January 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
